AU2014305646C1 - Contaminant removal method - Google Patents

Contaminant removal method Download PDF

Info

Publication number
AU2014305646C1
AU2014305646C1 AU2014305646A AU2014305646A AU2014305646C1 AU 2014305646 C1 AU2014305646 C1 AU 2014305646C1 AU 2014305646 A AU2014305646 A AU 2014305646A AU 2014305646 A AU2014305646 A AU 2014305646A AU 2014305646 C1 AU2014305646 C1 AU 2014305646C1
Authority
AU
Australia
Prior art keywords
apo
range
solution
virus
guhci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014305646A
Other languages
English (en)
Other versions
AU2014305646B2 (en
AU2014305646A1 (en
Inventor
Christoph Kempf
Martin Stucki
Yvonne VUCICA
Gary Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of AU2014305646A1 publication Critical patent/AU2014305646A1/en
Publication of AU2014305646B2 publication Critical patent/AU2014305646B2/en
Application granted granted Critical
Publication of AU2014305646C1 publication Critical patent/AU2014305646C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2014305646A 2013-08-08 2014-08-08 Contaminant removal method Active AU2014305646C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13179755.7 2013-08-08
EP13179755 2013-08-08
PCT/AU2014/000790 WO2015017888A1 (en) 2013-08-08 2014-08-08 Contaminant removal method

Publications (3)

Publication Number Publication Date
AU2014305646A1 AU2014305646A1 (en) 2016-02-18
AU2014305646B2 AU2014305646B2 (en) 2018-06-14
AU2014305646C1 true AU2014305646C1 (en) 2019-01-17

Family

ID=48948309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014305646A Active AU2014305646C1 (en) 2013-08-08 2014-08-08 Contaminant removal method

Country Status (13)

Country Link
US (3) US10087235B2 (cg-RX-API-DMAC7.html)
EP (2) EP3030578B1 (cg-RX-API-DMAC7.html)
JP (1) JP6530394B2 (cg-RX-API-DMAC7.html)
KR (1) KR102437202B1 (cg-RX-API-DMAC7.html)
CN (2) CN105452291B (cg-RX-API-DMAC7.html)
AU (1) AU2014305646C1 (cg-RX-API-DMAC7.html)
CA (1) CA2920391C (cg-RX-API-DMAC7.html)
DK (1) DK3030578T3 (cg-RX-API-DMAC7.html)
ES (1) ES2689333T3 (cg-RX-API-DMAC7.html)
HK (1) HK1225737B (cg-RX-API-DMAC7.html)
NZ (1) NZ631126A (cg-RX-API-DMAC7.html)
PL (1) PL3030578T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015017888A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3030578B1 (en) * 2013-08-08 2018-07-04 CSL Limited Contaminant removal method
TW201941813A (zh) * 2018-02-19 2019-11-01 美商拜耳保健有限責任公司 改良的濾膜及方法
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
WO2020202831A1 (ja) * 2019-03-29 2020-10-08 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
CN111351893A (zh) * 2020-04-28 2020-06-30 黄河三角洲京博化工研究院有限公司 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
WO2003105989A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
DK2183268T3 (da) * 2007-08-17 2013-01-21 Csl Behring Gmbh Fremgangsmåder til rensning af alpha-1-antitrypsin og apolipoprotein A-1
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
WO2011044545A2 (en) * 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
CN105396122B (zh) * 2010-06-30 2020-09-11 杰特有限公司 重建高密度脂蛋白制剂及其生产方法
CN105288589A (zh) * 2011-02-07 2016-02-03 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
NZ631116A (en) 2013-06-05 2018-07-27 Csl Ltd Process for preparing apolipoprotein a-i (apo a-i)
EP3030578B1 (en) * 2013-08-08 2018-07-04 CSL Limited Contaminant removal method
CN104017076B (zh) * 2014-01-06 2016-07-06 宁波博泰生物技术有限公司 载脂蛋白aⅰ抗血清的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM J-S. ET AL., "Manufacturing and shelf stability of reconstituted high-density lipoprotein for infusion therapy", BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, (2011-08-01), vol. 16, no. 4, pages 785 - 792 *
SCHLEGEL A. ET AL., "Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride", TRANSFUSION, (2001-03-01), vol. 41, no. 3, pages 382 - 389 *

Also Published As

Publication number Publication date
DK3030578T3 (en) 2018-10-15
WO2015017888A8 (en) 2015-10-01
WO2015017888A1 (en) 2015-02-12
JP2016528233A (ja) 2016-09-15
EP3418290A1 (en) 2018-12-26
JP6530394B2 (ja) 2019-06-12
CA2920391C (en) 2023-03-28
EP3030578B1 (en) 2018-07-04
US20190119354A1 (en) 2019-04-25
CN105452291B (zh) 2019-03-19
EP3030578A1 (en) 2016-06-15
KR20160040299A (ko) 2016-04-12
US10730927B2 (en) 2020-08-04
US20160176947A1 (en) 2016-06-23
AU2014305646B2 (en) 2018-06-14
US10087235B2 (en) 2018-10-02
EP3030578A4 (en) 2017-04-26
CA2920391A1 (en) 2015-02-12
US11732028B2 (en) 2023-08-22
CN109701004B (zh) 2022-11-08
HK1225737B (en) 2017-09-15
CN109701004A (zh) 2019-05-03
KR102437202B1 (ko) 2022-08-29
AU2014305646A1 (en) 2016-02-18
NZ631126A (en) 2018-06-29
CN105452291A (zh) 2016-03-30
PL3030578T3 (pl) 2018-12-31
US20210147509A1 (en) 2021-05-20
ES2689333T3 (es) 2018-11-13

Similar Documents

Publication Publication Date Title
US11732028B2 (en) Contaminant removal method
ES2221957T5 (es) Método para la eliminación cromatográfica de priones.
US5652339A (en) Method of producing reconstituted lipoproteins
EP2125861B1 (en) Method of purifying apolipoprotein a-1
HK1225737A1 (en) Contaminant removal method
HK40005666A (en) Contaminant removal method
RU2681413C2 (ru) Способы получения нового поколения безопасных с биологической точки зрения продуктов klh, применяемых для лечения рака, для разработки коньюгированных терапевтических вакцин и в качестве стимулирующих средств
EP3154597B1 (en) Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 AUG 2018

TH Corrigenda

Free format text: IN VOL 32 , NO 39 , PAGE(S) 5462 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME CSL LIMITED, APPLICATION NO. 2014203072 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 22 AUGUST 2018, 7 SEPTEMBER 2018 AND 26 SEPTEMBER 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 22 AUG 2018, 07 SEP 2018 AND 26 SEP 2018

FGA Letters patent sealed or granted (standard patent)